Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma.

Alagpulinsa DA, Kumar S, Talluri S, Nanjappa P, Buon L, Chakraborty C, Samur MK, Szalat R, Shammas MA, Munshi NC.

Blood Adv. 2019 Dec 10;3(23):3968-3972. doi: 10.1182/bloodadvances.2019000181. No abstract available.

PMID:
31805191
2.

MUS81 Participates in the Progression of Serous Ovarian Cancer Associated With Dysfunctional DNA Repair System.

Lu R, Xie S, Wang Y, Zheng H, Zhang H, Deng M, Shi W, Zhong A, Chen M, Zhang M, Xu X, Shammas MA, Guo L.

Front Oncol. 2019 Nov 15;9:1189. doi: 10.3389/fonc.2019.01189. eCollection 2019.

3.

The roles of homologous recombination and the immune system in the genomic evolution of cancer.

Nandi B, Talluri S, Kumar S, Yenumula C, Gold JS, Prabhala R, Munshi NC, Shammas MA.

J Transl Sci. 2019 Apr;5(2). doi: 10.15761/JTS.1000282. Epub 2018 Oct 1.

4.

Role of apurinic/apyrimidinic nucleases in the regulation of homologous recombination in myeloma: mechanisms and translational significance.

Kumar S, Talluri S, Pal J, Yuan X, Lu R, Nanjappa P, Samur MK, Munshi NC, Shammas MA.

Blood Cancer J. 2018 Sep 25;8(10):92. doi: 10.1038/s41408-018-0129-9.

5.

Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia.

Li N, Lopez MA, Linares M, Kumar S, Oliva S, Martinez-Lopez J, Xu L, Xu Y, Perini T, Senapedis W, Baloglu E, Shammas MA, Hunter Z, Anderson KC, Treon SP, Munshi NC, Fulciniti M.

Clin Cancer Res. 2019 Jan 1;25(1):369-377. doi: 10.1158/1078-0432.CCR-18-1776. Epub 2018 Sep 11.

PMID:
30206161
6.

Genomic patterns of progression in smoldering multiple myeloma.

Bolli N, Maura F, Minvielle S, Gloznik D, Szalat R, Fullam A, Martincorena I, Dawson KJ, Samur MK, Zamora J, Tarpey P, Davies H, Fulciniti M, Shammas MA, Tai YT, Magrangeas F, Moreau P, Corradini P, Anderson K, Alexandrov L, Wedge DC, Avet-Loiseau H, Campbell P, Munshi N.

Nat Commun. 2018 Aug 22;9(1):3363. doi: 10.1038/s41467-018-05058-y.

7.

Phosphatidylserine-exposing blood cells and microparticles induce procoagulant activity in non-valvular atrial fibrillation.

Wang L, Bi Y, Yu M, Li T, Tong D, Yang X, Zhang C, Guo L, Wang C, Kou Y, Dong Z, Novakovic VA, Tian Y, Kou J, Shammas MA, Shi J.

Int J Cardiol. 2018 May 1;258:138-143. doi: 10.1016/j.ijcard.2018.01.116.

PMID:
29544920
8.

Impact of RAD51C-mediated Homologous Recombination on Genomic Integrity in Barrett's Adenocarcinoma Cells.

Pal J, Nanjappa P, Kumar S, Shi J, Buon L, Munshi NC, Shammas MA.

J Gastroenterol Hepatol Res. 2017;6(1):2286-2295. doi: 10.17554/j.issn.2224-3992.2017.06.687. Epub 2017 Feb 21.

9.

Risk Assessment to Evaluate if Crayons Complying with the Consumer Product Safety Improvement Act of 2008 for Lead, Also Comply with California Proposition 65.

Ahmad GR, Kumar S, Ahmad D, Shammas MA.

Front Public Health. 2017 Jun 2;5:130. doi: 10.3389/fpubh.2017.00130. eCollection 2017. No abstract available.

10.

Nucleotide excision repair is a potential therapeutic target in multiple myeloma.

Szalat R, Samur MK, Fulciniti M, Lopez M, Nanjappa P, Cleynen A, Wen K, Kumar S, Perini T, Calkins AS, Reznichenko E, Chauhan D, Tai YT, Shammas MA, Anderson KC, Fermand JP, Arnulf B, Avet-Loiseau H, Lazaro JB, Munshi NC.

Leukemia. 2018 Jan;32(1):111-119. doi: 10.1038/leu.2017.182. Epub 2017 Jun 7.

11.

Redefining Board Certified Toxicologist by Consumer Products Safety Commission May Increase Potential Risk of Exposure to Carcinogens among Consumers in United States of America.

Unmack JL, Bud Jenkins VC, Shammas MA.

Front Public Health. 2017 Feb 28;5:29. doi: 10.3389/fpubh.2017.00029. eCollection 2017. No abstract available.

12.

Inclusion of "Toxicological Review Expiry Dates" in Art Material Labels May Further Reduce the Risk of Chronic Toxicity, Including That of Cancer.

Shammas MA, Rajput SA, Ahmad D, Ahmed M, Mustafa Z, Ahmad G.

Front Oncol. 2016 Jan 20;6:4. doi: 10.3389/fonc.2016.00004. eCollection 2016. Review. No abstract available.

13.

High frequency and poor prognosis of late childhood BCR-ABL-positive and MLL-AF4-positive ALL define the need for advanced molecular diagnostics and improved therapeutic strategies in pediatric B-ALL in Pakistan.

Iqbal Z, Akhtar T, Awan T, Aleem A, Sabir N, Rasool M, Absar M, Akram AM, Shammas MA, Shah IH, Khalid M, Taj AS, Jameel A, Alanazi A, Gill AT, Hashmi JA, Hussain A, Sabar MF, Khalid AM, Qazi MH, Karim S, Siddiqi MH, Mahmood A, Iqbal M, Saeed A, Irfan MI.

Mol Diagn Ther. 2015 Oct;19(5):277-87. doi: 10.1007/s40291-015-0149-0.

PMID:
26266519
14.

Suggested safe harbor limit for titanium dioxide: an exposure level which protects consumers from cancer incidence.

Shammas MA, Ahmad D, Nguyen MD, Rajput S, Unmack J, Ahmad G.

Front Oncol. 2015 Mar 26;5:76. doi: 10.3389/fonc.2015.00076. eCollection 2015. Review. No abstract available.

15.

Differential and limited expression of mutant alleles in multiple myeloma.

Rashid NU, Sperling AS, Bolli N, Wedge DC, Van Loo P, Tai YT, Shammas MA, Fulciniti M, Samur MK, Richardson PG, Magrangeas F, Minvielle S, Futreal PA, Anderson KC, Avet-Loiseau H, Campbell PJ, Parmigiani G, Munshi NC.

Blood. 2014 Nov 13;124(20):3110-7. doi: 10.1182/blood-2014-04-569327. Epub 2014 Sep 18.

16.

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, Dawson KJ, Iorio F, Nik-Zainal S, Bignell GR, Hinton JW, Li Y, Tubio JM, McLaren S, O' Meara S, Butler AP, Teague JW, Mudie L, Anderson E, Rashid N, Tai YT, Shammas MA, Sperling AS, Fulciniti M, Richardson PG, Parmigiani G, Magrangeas F, Minvielle S, Moreau P, Attal M, Facon T, Futreal PA, Anderson KC, Campbell PJ, Munshi NC.

Nat Commun. 2014;5:2997. doi: 10.1038/ncomms3997.

17.

Biology of telomeres: importance in etiology of esophageal cancer and as therapeutic target.

Pal J, Gold JS, Munshi NC, Shammas MA.

Transl Res. 2013 Dec;162(6):364-70. doi: 10.1016/j.trsl.2013.09.003. Epub 2013 Oct 1. Review.

18.

Targeting homologous recombination and telomerase in Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth.

Lu R, Pal J, Buon L, Nanjappa P, Shi J, Fulciniti M, Tai YT, Guo L, Yu M, Gryaznov S, Munshi NC, Shammas MA.

Oncogene. 2014 Mar 20;33(12):1495-505. doi: 10.1038/onc.2013.103. Epub 2013 Apr 22.

19.

Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.

Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, Cantafio ME, GullĂ  A, Conforti F, Morelli E, Tomaino V, Rossi M, Negrini M, Ferrarini M, Caraglia M, Shammas MA, Munshi NC, Anderson KC, Neri A, Tagliaferri P, Tassone P.

Clin Cancer Res. 2012 Nov 15;18(22):6260-70. doi: 10.1158/1078-0432.CCR-12-1708. Epub 2012 Oct 3.

20.

Repetitive sequences, genomic instability and Barrett's esophageal adenocarcinoma.

Shammas MA.

Mob Genet Elements. 2011 Sep;1(3):208-212. Epub 2011 Sep 1.

21.

Targeting PI3K and RAD51 in Barrett's adenocarcinoma: impact on DNA damage checkpoints, expression profile and tumor growth.

Pal J, Fulciniti M, Nanjappa P, Buon L, Tai YT, Tassone P, Munshi NC, Shammas MA.

Cancer Genomics Proteomics. 2012 Mar-Apr;9(2):55-66.

22.

Purification of diseased cells from Barrett's esophagus and related lesions by laser capture microdissection.

Shammas MA, Rao MY.

Methods Mol Biol. 2011;755:181-7. doi: 10.1007/978-1-61779-163-5_14.

PMID:
21761303
23.

Genomic evolution in Barrett's adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome.

Pal J, Bertheau R, Buon L, Qazi A, Batchu RB, Bandyopadhyay S, Ali-Fehmi R, Beer DG, Weaver DW, Shmookler Reis RJ, Goyal RK, Huang Q, Munshi NC, Shammas MA.

Oncogene. 2011 Aug 18;30(33):3585-98. doi: 10.1038/onc.2011.83. Epub 2011 Mar 21.

24.

Anticancer activity of a broccoli derivative, sulforaphane, in barrett adenocarcinoma: potential use in chemoprevention and as adjuvant in chemotherapy.

Qazi A, Pal J, Maitah M, Fulciniti M, Pelluru D, Nanjappa P, Lee S, Batchu RB, Prasad M, Bryant CS, Rajput S, Gryaznov S, Beer DG, Weaver DW, Munshi NC, Goyal RK, Shammas MA.

Transl Oncol. 2010 Dec 1;3(6):389-99.

25.

Telomeres, lifestyle, cancer, and aging.

Shammas MA.

Curr Opin Clin Nutr Metab Care. 2011 Jan;14(1):28-34. doi: 10.1097/MCO.0b013e32834121b1. Review.

26.

Sulforaphane induces cell cycle arrest by protecting RB-E2F-1 complex in epithelial ovarian cancer cells.

Bryant CS, Kumar S, Chamala S, Shah J, Pal J, Haider M, Seward S, Qazi AM, Morris R, Semaan A, Shammas MA, Steffes C, Potti RB, Prasad M, Weaver DW, Batchu RB.

Mol Cancer. 2010 Mar 2;9:47. doi: 10.1186/1476-4598-9-47.

27.

Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells.

Kumar S, Bryant CS, Chamala S, Qazi A, Seward S, Pal J, Steffes CP, Weaver DW, Morris R, Malone JM, Shammas MA, Prasad M, Batchu RB.

Mol Cancer. 2009 Apr 22;8:26. doi: 10.1186/1476-4598-8-26.

28.

Dysfunctional homologous recombination mediates genomic instability and progression in myeloma.

Shammas MA, Shmookler Reis RJ, Koley H, Batchu RB, Li C, Munshi NC.

Blood. 2009 Mar 5;113(10):2290-7. doi: 10.1182/blood-2007-05-089193. Epub 2008 Dec 2.

29.

Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.

Song W, van der Vliet HJ, Tai YT, Prabhala R, Wang R, Podar K, Catley L, Shammas MA, Anderson KC, Balk SP, Exley MA, Munshi NC.

Clin Cancer Res. 2008 Nov 1;14(21):6955-62. doi: 10.1158/1078-0432.CCR-07-5290.

30.

Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo.

Shammas MA, Qazi A, Batchu RB, Bertheau RC, Wong JY, Rao MY, Prasad M, Chanda D, Ponnazhagan S, Anderson KC, Steffes CP, Munshi NC, De Vivo I, Beer DG, Gryaznov S, Weaver DW, Goyal RK.

Clin Cancer Res. 2008 Aug 1;14(15):4971-80. doi: 10.1158/1078-0432.CCR-08-0473.

31.

Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo.

Shammas MA, Koley H, Bertheau RC, Neri P, Fulciniti M, Tassone P, Blotta S, Protopopov A, Mitsiades C, Batchu RB, Anderson KC, Chin A, Gryaznov S, Munshi NC.

Leukemia. 2008 Jul;22(7):1410-8. doi: 10.1038/leu.2008.81. Epub 2008 May 1.

32.

Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications.

Shammas MA, Neri P, Koley H, Batchu RB, Bertheau RC, Munshi V, Prabhala R, Fulciniti M, Tai YT, Treon SP, Goyal RK, Anderson KC, Munshi NC.

Blood. 2006 Oct 15;108(8):2804-10. Epub 2006 Jun 29.

33.

Dysfunctional T regulatory cells in multiple myeloma.

Prabhala RH, Neri P, Bae JE, Tassone P, Shammas MA, Allam CK, Daley JF, Chauhan D, Blanchard E, Thatte HS, Anderson KC, Munshi NC.

Blood. 2006 Jan 1;107(1):301-4. Epub 2005 Sep 8.

34.

Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential.

Shammas MA, Koley H, Batchu RB, Bertheau RC, Protopopov A, Munshi NC, Goyal RK.

Mol Cancer. 2005 Jul 15;4:24.

35.

A clinically relevant SCID-hu in vivo model of human multiple myeloma.

Tassone P, Neri P, Carrasco DR, Burger R, Goldmacher VS, Fram R, Munshi V, Shammas MA, Catley L, Jacob GS, Venuta S, Anderson KC, Munshi NC.

Blood. 2005 Jul 15;106(2):713-6. Epub 2005 Apr 7.

36.

Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.

Tassone P, Goldmacher VS, Neri P, Gozzini A, Shammas MA, Whiteman KR, Hylander-Gans LL, Carrasco DR, Hideshima T, Shringarpure R, Shi J, Allam CK, Wijdenes J, Venuta S, Munshi NC, Anderson KC.

Blood. 2004 Dec 1;104(12):3688-96. Epub 2004 Aug 3.

PMID:
15292058
37.

In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.

Tassone P, Gozzini A, Goldmacher V, Shammas MA, Whiteman KR, Carrasco DR, Li C, Allam CK, Venuta S, Anderson KC, Munshi NC.

Cancer Res. 2004 Jul 1;64(13):4629-36.

38.

Growth arrest, apoptosis, and telomere shortening of Barrett's-associated adenocarcinoma cells by a telomerase inhibitor.

Shammas MA, Koley H, Beer DG, Li C, Goyal RK, Munshi NC.

Gastroenterology. 2004 May;126(5):1337-46.

PMID:
15131795
39.

Targeting the single-strand G-rich overhang of telomeres with PNA inhibits cell growth and induces apoptosis of human immortal cells.

Shammas MA, Liu X, Gavory G, Raney KD, Balasubramanian S, Shmookler Reis RJ.

Exp Cell Res. 2004 Apr 15;295(1):204-14.

PMID:
15051503
40.

Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma.

Shammas MA, Shmookler Reis RJ, Li C, Koley H, Hurley LH, Anderson KC, Munshi NC.

Clin Cancer Res. 2004 Jan 15;10(2):770-6.

41.

Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells.

Akiyama M, Hideshima T, Shammas MA, Hayashi T, Hamasaki M, Tai YT, Richardson P, Gryaznov S, Munshi NC, Anderson KC.

Cancer Res. 2003 Oct 1;63(19):6187-94.

42.

Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma.

Shammas MA, Shmookler Reis RJ, Akiyama M, Koley H, Chauhan D, Hideshima T, Goyal RK, Hurley LH, Anderson KC, Munshi NC.

Mol Cancer Ther. 2003 Sep;2(9):825-33.

43.

Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis.

Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, O'Connor SM, Fenton JA, Hideshima T, Chauhan D, Tai IT, Robinson E, Auclair D, Rees K, Gonzalez D, Ashcroft AJ, Dasgupta R, Mitsiades C, Mitsiades N, Chen LB, Wong WH, Munshi NC, Morgan GJ, Anderson KC.

Blood. 2003 Dec 15;102(13):4504-11. Epub 2003 Aug 28.

PMID:
12947006
44.

Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma.

Iyer R, Ding L, Batchu RB, Naugler S, Shammas MA, Munshi NC.

Leuk Res. 2003 Jan;27(1):73-8.

PMID:
12479855
45.
46.

Adeno-associated virus protects the retinoblastoma family of proteins from adenoviral-induced functional inactivation.

Batchu RB, Shammas MA, Wang JY, Freeman J, Rosen N, Munshi NC.

Cancer Res. 2002 May 15;62(10):2982-5.

47.

Expression of AAV Rep proteins in SV40-transformed and untransformed cells: reciprocal interaction with host DNA synthesis.

Batchu RB, Shammas MA, Wang JY, Shmookler Reis RJ, Munshi NC.

Intervirology. 2001;44(5):298-305.

PMID:
11684891
48.

Dual level inhibition of E2F-1 activity by adeno-associated virus Rep78.

Batchu RB, Shammas MA, Wang JY, Munshi NC.

J Biol Chem. 2001 Jun 29;276(26):24315-22. Epub 2001 Apr 6.

49.

Telomerase inhibition by peptide nucleic acids reverses 'immortality' of transformed human cells.

Shammas MA, Simmons CG, Corey DR, Shmookler Reis RJ.

Oncogene. 1999 Nov 4;18(46):6191-200.

50.

Interaction of adeno-associated virus Rep78 with p53: implications in growth inhibition.

Batchu RB, Shammas MA, Wang JY, Munshi NC.

Cancer Res. 1999 Aug 1;59(15):3592-5.

Supplemental Content

Loading ...
Support Center